NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC)
نویسندگان
چکیده
منابع مشابه
phase ii study of gemcitabine and cisplatin regimen in advanced non-small cell lung cancer (nsclc).
background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...
متن کاملRadio(chemo)therapy in locally advanced nonsmall cell lung cancer.
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsmall cell lung cancer (NSCLC). Treatment outcomes have improved over the last decades. Several treatment regimens have been shown effective and safe. This review summarises the results of significant studies between 1996 and 2015 on concomitant and sequential radiochemotherapy regimens and radiati...
متن کاملphase ii study of gemcitabine and cisplatin in advanced non-small cell lung cancer
cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the efficacy and safety of gemcitabine and cisplatin combination. twentythree pati...
متن کاملWeekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial.
BACKGROUND Open-label, single-centre Phase II trial evaluating the toxicity and antitumour activity of weekly docetaxel in the second-line management of advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Treatment comprised docetaxel 35 mg/m2 weekly for 6 weeks followed by 2 weeks' rest for a maximum of 3 cycles. RESULTS Thirty-six patients received 220 weekly doses of doceta...
متن کاملPaclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
PURPOSE Studies conducted by the Eastern Cooperative Oncology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC. PATIENTS AND METHODS Eligibility included p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2016
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2015.12.081